Literature DB >> 32317236

Adaptive servo-ventilation therapy does not favourably alter sympatho-vagal balance in sleeping patients with systolic heart failure and central apnoeas: Preliminary data.

Martha Gorbachevski1, Jens Spiesshoefer2, Michael Arzt3, Olaf Oldenburg4, Sara Becker1, Izabela Tuleta5, Michele Emdin6, Claudio Passino6, Paolo Sciarrone7, Matthias Boentert8, Alberto Giannoni6.   

Abstract

BACKGROUND: In contrast to continuous positive airway pressure (CPAP), the use of adaptive servo-ventilation (ASV) for treatment of central sleep apnoea (CSA) was associated with increased mortality in patients with chronic systolic heart failure (CHF). In order to characterize the interplay between sleep-disordered breathing, CHF and sympathovagal balance (SVB) this study investigated the effect of nocturnal CPAP and ASV on SVB in CSA patients with or without CHF.
METHODS: Thirty-seven patients with ongoing positive airway pressure therapy (CPAP or ASV) for CSA (17 patients with systolic CHF - left ventricular ejection fraction <50% - and 20 patients with CSA but no CHF) underwent evaluation of SVB (spectral analysis of heart rate -HRV- and diastolic blood pressure variability) during full nocturnal polysomnography. The night was randomly split into equal parts including no treatment (NT), automatic CPAP and ASV. Data analysis was restricted to stable N2 sleep.
RESULTS: In patients with CSA and systolic CHF, neither automatic CPAP nor ASV showed favourable effects on parameters reflecting SVB during N2 sleep (all p > 0.05). In contrast, in subjects with CSA without CHF automatic CPAP, but not ASV, favourably altered SVB by decreasing the low frequency and increasing the high frequency component of HRV (both p = 0.03).
CONCLUSIONS: Effects of various modes of positive airway pressure therapy of CSA on SVB during sleep depend on the mode of pressure support and underlying cardiac function. Automatic CPAP but not ASV favourably influences SVB in subjects without CHF, whereas both interventions leave SVB unchanged in patients with CHF.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adaptive servoventilation; Automatic continuous positive airway pressure; Central sleep apnoea; Heart failure; Sympathovagal balance

Mesh:

Year:  2020        PMID: 32317236     DOI: 10.1016/j.ijcard.2020.03.078

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Cheyne-Stokes Breathing as a Predictive Indicator of Heart Failure in Patients With Obstructive Sleep Apnea; A Retrospective Case Control Study Using Continuous Positive Airway Pressure Remote Monitoring Data.

Authors:  Kimimasa Saito; Yoko Takamatsu
Journal:  Front Cardiovasc Med       Date:  2022-02-07

2.  Effect of Pulse Indicator Continuous Cardiac Output Monitoring on Septic Shock Patients: A Meta-Analysis.

Authors:  Bin Wang; Lijuan Cai; Bin Lin; Qiongxiao He; Xuejun Ding
Journal:  Comput Math Methods Med       Date:  2022-04-16       Impact factor: 2.809

3.  Periodic breathing in patients with stable obstructive sleep apnea on long-term continuous positive airway pressure treatment: a retrospective study using CPAP remote monitoring data.

Authors:  Kimimasa Saito; Yoko Takamatsu
Journal:  Sleep Breath       Date:  2021-10-14       Impact factor: 2.655

4.  Patterns of adaptive servo-ventilation settings in a real-life multicenter study: pay attention to volume! : Adaptive servo-ventilation settings in real-life conditions.

Authors:  Dany Jaffuel; Claudio Rabec; Carole Philippe; Jean-Pierre Mallet; Marjolaine Georges; Stefania Redolfi; Alain Palot; Carey M Suehs; Erika Nogue; Nicolas Molinari; Arnaud Bourdin
Journal:  Respir Res       Date:  2020-09-21

5.  Improving Nocturnal Hypoxemic Burden with Transvenous Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea.

Authors:  Olaf Oldenburg; Maria Rosa Costanzo; Robin Germany; Scott McKane; Timothy E Meyer; Henrik Fox
Journal:  J Cardiovasc Transl Res       Date:  2020-08-12       Impact factor: 4.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.